Clinical Trials
14
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
PROspective Master-protocol for Evaluation of Systemic THErapeutics in Elderly With Thoracic Malignancies
- Conditions
- Non Small Cell Lung CancerLung Cancer
- First Posted Date
- 2024-10-17
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Groupe Francais De Pneumo-Cancerologie
- Target Recruit Count
- 500
- Registration Number
- NCT06646471
- Locations
- 🇫🇷
CH du Pays d Aix, Aix En Provence, France
🇫🇷Hôpital Henri Duffaut, Avignon, France
🇫🇷CH Bastia, Bastia, France
Trial for Local Ablative Treatment (LAT) Optimization in Patients With Advanced Non-Small Cells Lung Cancer (NSCLC) Presenting an Anaplastic Lymphoma Kinase (ALK) Rearrangement Treated by Brigatinib
- Conditions
- NSCLC
- Interventions
- Biological: Blood samples for HematologyBiological: Blood samples for ChemistryBiological: Blood sample for liver function testsBiological: Pregnancy testProcedure: Tumour assessmentProcedure: Local Ablative Therapy (LAT)
- First Posted Date
- 2024-10-01
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Groupe Francais De Pneumo-Cancerologie
- Target Recruit Count
- 45
- Registration Number
- NCT06620835
- Locations
- 🇫🇷
CHU de Brest, Brest, France
🇫🇷Centre François Baclesse, Caen, France
🇫🇷CH Métropole-Savoie, Chambery, France
Mechanisms of Resistance to Amivantamab in Patients With NSCLC With EGFR Exon 20 Insertion
- Conditions
- Non-small Cell Lung CancerEGFR Exon 20 Insertion Mutation
- First Posted Date
- 2024-02-08
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Groupe Francais De Pneumo-Cancerologie
- Target Recruit Count
- 30
- Registration Number
- NCT06247826
- Locations
- 🇫🇷
Oncologie Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France
🇫🇷Centre Hospitalier du Morvan, Brest, France
🇫🇷Pneumologie Centre Hospitalier Intercommunal de Créteil, Creteil, France
Observational Study in Patients With Previously Unresectable Malignant Pleural Mesothelioma Treated With Nivolumab and Ipilimumab (MESO-IMMUNE)
- Conditions
- Malignant Pleural MesotheliomaUnresectable Malignant Neoplasm
- First Posted Date
- 2022-04-04
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Groupe Francais De Pneumo-Cancerologie
- Target Recruit Count
- 200
- Registration Number
- NCT05308966
- Locations
- 🇫🇷
CHU du Pays d'Aix, Aix-en-Provence, France
🇫🇷CH Albi, Albi, France
🇫🇷CHU Angers, Angers, France
Analysis of Biological Characteristics of Advanced ALK-rearranged NSCLC
- Conditions
- Non-small Cell Lung CancerALK Gene Rearrangement Positive
- First Posted Date
- 2021-11-17
- Last Posted Date
- 2023-10-19
- Lead Sponsor
- Groupe Francais De Pneumo-Cancerologie
- Target Recruit Count
- 100
- Registration Number
- NCT05122806
- Locations
- 🇫🇷
Pneumologie CHU Félix Guyon, Saint-Denis, La Réunion, France
🇫🇷Centre Hospitalier d'Aix en Provence, Aix En Provence, France
🇫🇷Pneumologie CHU, Amiens, France
- Prev
- 1
- 2
- 3
- Next